Objectives: Iliocaval obstruction is a significant cause of morbidity, with patients suffering spectrum of symptoms including pulmonary embolus, painful lower extremity swelling and recurrent deep venous thrombosis. The aim of our study was to assess the capability of certain magnetic resonance imaging (MRI) sequences to determine age thresholds of experimentally created inferior vena cava (IVC) thrombosis in pigs. Ultimately, the goal is to define MRI as an imaging modality that would allow noninvasive assessment of specific stages of venous remodeling.
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Augmentation of Peak Venous Velocity in Venous Insufficiency Using a Novel Mechanical Intermittent Sequential Compression Device
Objectives: A novel mechanical device for lower leg intermittent sequential compression was specifically designed to address the limitations of intermittent pneumatic compression (IPC) for the treatment of venous leg ulcers (VLU). The use of intermittent mechanical compression (IMC) allows the delivery of more rapid compression cycles than IPC, which have been show in a randomized trial to improve VLU healing. The device is portable and light-weight, which has the potential to improve compliance by allowing the patient to remain fully mobile during therapy. Finally, the device can monitor compression dose, compliance and response so that more informed therapeutic decisions can be made.
Methods: Ten patients with CEAP three to six venous insufficiency were recruited into an IRB approved study of venous flow augmentation. The primary end point for the study was augmentation of venous blood flow as measured by peak venous velocity. Patients who passed a DVT screen went on to have measurement of peak venous velocity in cm/s at the popliteal and femoral veins for the following conditions: (1) baseline (2) novel mechanical device in low setting (3) novel mechanical device in high setting. In 5 patients, an additional measurement of peak venous velocity in cm/s at the popliteal and femoral veins was completed while wearing a commercially available portable intermittent pneumatic compression device. The study was powered for the primary end point at 80% to determine if blood flow could be augmented from 15 cm/s to 30 cm/s with a pretest predicted standard deviation of 8.
Results: Both low and high settings of the IMC device resulted in higher average peak venous velocities when compared with both baseline and the IPC device (P < .05). Figs 1 and 2 show the average popliteal and femoral venous velocities respectively for baseline, IPC, IMC low setting and IMC high setting with 95% confidence intervals.
Conclusions: A novel mechanical device for lower leg graded intermittent sequential compression addresses significant limitations of portable IPC therapy for VLU treatment by providing rapid compression cycles in a truly wearable device that offers the additional benefit of monitoring compression dose and patient compliance. The device significantly increases the augmentation of venous flow as measured by peak venous velocity in both the popliteal and femoral veins in patients with CEAP three to six venous insufficiency. Future studies are planned to determine if the rapid compressions cycles of IMC will improve venous ulcer healing. Objectives: Radiofrequency ablation (RFA) and endovascular laser ablation (EVLA) have become popular techniques for treating varicose veins. Endothermal heat induced thrombosis (EHIT) is a complication unique to endovenous ablation. It reflects the extension of the thrombus from the ablated saphenous vein into deep venous system. Using national data, we want to determine patient factors and operative parameters associated with a higher incidence of EHIT.
Methods: We performed a retrospective analysis of the national Vascular Quality Initiative (VQI) Varicose Vein Registry for all varicose vein procedures by RFA and EVLA performed between March 2014 and May 2017. To accurately detect all EHIT cases, we only included ablations that had a follow-up between 2 and 28 days. EHIT was classified according to the Kabnick criteria into low grade (class 1 and 2) and high grade (class 3 and 4) as per the VQI. Variables collected included patients demographics, comorbidities, procedural details and complications. After stratifying by the type of vein ablated (great saphenous vs small saphenous), univariate followed by multivariate logistic regression was performed to determine the significant risk factors for EHIT.
Results: During the study period, 11,041 vein ablations were recorded in the national registry; of these 2353 met the inclusion criteria. The average age was 56 years and 70% were female. Fifty-five percent of procedures were RFA and the rest were EVLA. Ninety percent of procedures were performed to ablate the great saphenous vein. Fortyone patients (1.6%) developed EHIT during the follow-up period; 90% belonged to Kabnick class 1 and 2. The only significant risk factor for EHIT using multivariate logistic regression was increasing diameter of the great saphenous (OR, 1.014 for every 1 mm increase in vein diameter; P ¼ .001).Type of ablation energy used (RFA vs EVLA), concomitant stab phlebectomy, and preoperative anticoagulation were not associated with EHIT occurrence.
Conclusions: EHIT is a rare complication after endovenous varicose vein ablation, and it is not affected by the type of vein ablation. Increasing great saphenous vein diameter was the only significant risk factor for EHIT.
Author Disclosures: S. Ahsan: Nothing to disclose; Z. Al Adas: Nothing to disclose; L. Kabbani: Nothing to disclose; N. Kennedy: Nothing to disclose; J. C. Lin: Nothing to disclose; A. Shepard: Nothing to disclose; M. R. Weaver: Nothing to disclose. Methods: This was an institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study performed at two collaborating quaternary care institution over a 14-month period. After process maps for iliocaval reconstruction were prepared, staff practical capacity rates and consumable equipment costs were analyzed via a time-driven activity-based costing methodology. Sensitivity analyses were performed to identify primary cost drivers (Table) .
Results: Average procedure duration was 6.24 hours (range, 5.75-7.15 hours). Base case cost, per case, for iliocaval reconstruction was $20,698.83. Multivariate sensitivity analyses performed with all minimum and maximum values for cost input variables yielded a cost range of $9,988.18 (minimum) to $42,632.02 (maximum). Using local salary information and negotiated prices for materials as cost parameters, the true cost per case, for iliocaval reconstruction was $21,159.64. Univariate analysis demonstrated that the primary driver of staffing costs was the length of time the attending anesthesiologist was present (minimum $20,031.53; maximum $21,049.71). Less significant staffing costs included: anesthesiologist wages, certified registered nurse anesthetist wages, time the certified registered nurse anesthetist was present, nurse wages, total nursehours per procedure, technician wages, total technician-hours per procedure, attending endovascular proceduralists wages, the length of time the attending endovascular proceduralists was present, fellow wages, and the length of time the fellow was present. The predominant modifiable cost drivers included the cost of stents (minimum $19,655.73 ; maximum $31,048.84), number of stents used (minimum $18,976.01; maximum $23,409.69), the cost of catheters used (minimum $19,308.96; maximum $24,157.21) , and the number of catheters used (minimum $20,033.32; maximum $21,364.34) . Less significant disposable cost drivers included: sheath costs, number of sheaths used, guidewire costs, number of guidewires used, balloon catheter costs, and the number of balloon catheters used.
Conclusions: Anesthesia staffing costs, stent pricing, the number of stents used, are large, potentially modifiable drivers of overall cost for endovascular iliocaval reconstructions. Additional studies are necessary to define an iliocaval reconstruction protocol that delivers cost savings without compromising outcomes.
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